Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 12/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 12/20 | 0.36 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.33 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.33 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.33 |
| ▸ | HRH1 | P35367 | 1/20 | 0.32 |
| ▸ | NCF1 | P14598 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 2/20 | 0.32 |
| ▸ | HTR2B | P41595 | 2/20 | 0.32 |
| ▸ | CASP1 | P29466 | 1/20 | 0.32 |
| ▸ | CASP4 | P49662 | 1/20 | 0.32 |
| ▸ | CASP5 | P51878 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30169373 | 1.00 | CHRNB2 (0.36) | CHRNB2CHRNA4CXCR4CHRNA1CHRNA7 | |
| SCHEMBL860227 | 0.84 | HRH1 (0.41) | CHRNB2CHRNA4CHRNA1CHRNA7HRH1 | |
| SCHEMBL15310285 | 0.79 | TDP1 (0.36) | CHRNB2CHRNA4CXCR4CHRNA1CHRNA7 | |
| SCHEMBL9042088 | 0.78 | — | — | |
| SCHEMBL18932504 | 0.76 | — | — | |
| SCHEMBL15526123 | 0.76 | USP2 (0.40) | CHRNB2CHRNA4CHRNA1CHRNA7HRH1 | |
| SCHEMBL24277249 | 0.75 | KDM4E (0.39) | HRH1HTR2CHTR2BCASP1CASP4 | |
| SCHEMBL10437043 | 0.74 | SMN1; SMN2 (0.43) | CHRNB2CHRNA4CHRNA1CHRNA7HRH1 | |
| SCHEMBL436647 | 0.73 | CHRNB2 (0.33) | CHRNB2CHRNA4CXCR4CHRNA1CHRNA7 | |
| SCHEMBL7302082 | 0.73 | HTR2C (0.39) | HRH1NCF1HTR2CHTR2BCASP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250059221-A1 | STAT DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-02-20 | — | — | US | disclosed |
| US-12077555-B2 | STAT degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2024-09-03 | — | — | US | disclosed |
| US-11746120-B2 | Stat degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-20230120381-A1 | STAT DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-04-20 | — | — | US | disclosed |
| US-20230084113-A1 | STAT DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-03-16 | — | — | US | disclosed |
| US-11485750-B1 | STAT degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2022-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230084113-A1 | STAT DEGRADERS AND USES THEREOF | STAT4, STAT1, STAT3 | CHRNB2 4806/4885CHRNA4 4774/4885CXCR4 4003/4885 |
| US-20230120381-A1 | STAT DEGRADERS AND USES THEREOF | STAT4, STAT1, STAT3 | CHRNB2 4806/4885CHRNA4 4774/4885CXCR4 4003/4885 |
| US-12077555-B2 | STAT degraders and uses thereof | STAT4, STAT1, STAT3 | CHRNB2 4806/4885CHRNA4 4774/4885CXCR4 4003/4885 |
| US-20250059221-A1 | STAT DEGRADERS AND USES THEREOF | STAT4, STAT1, STAT3 | CHRNB2 4806/4885CHRNA4 4774/4885CXCR4 4003/4885 |
| US-11746120-B2 | Stat degraders and uses thereof | STAT4, STAT1, STAT3 | CHRNB2 4806/4885CHRNA4 4774/4885CXCR4 4003/4885 |
| US-11485750-B1 | STAT degraders and uses thereof | STAT4, STAT1, STAT3 | CHRNB2 4806/4885CHRNA4 4774/4885CXCR4 4003/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.